专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明专利

ES2582861T3 Ensayo de sangre completa para medir la activación de AMPK 未知
公开(公告)号：ES2582861T3
公开(公告)日：2016-09-15
申请号：ES11811474
申请日：2011-12-22
申请人： RIGEL PHARMACEUTICALS INC
发明人： MARKOVSTOV VADIM , HITOSHI YASUMICHI
IPC分类号： G01N33/50 , C12N9/12
摘要： Un método para evaluar el estado de energía de un sujeto que comprende: a) marcar células de una muestra sanguínea del sujeto usando un anticuerpo que se une específicamente con fosfo- AMPK, fosfo-acetil-CoA carboxilasa o fosfo-HMG-CoA reductasa, para producir una muestra marcada; y b) medir la unión de anticuerpo con células individuales de una población de células sanguíneas de dicha muestra marcada usando citometría de flujo, obteniendo de este modo una evaluación de la activación de AMPK de dicha población de células, en la que la activación de AMPK evaluada en dicha población de células puede usarse para evaluar el estado de energía del sujeto.

42. 发明专利

ZA201300374B AMPK-ACTIVATING HETEROCYCLIC COMPOUND AND METHODS FOR USING THE SAME 未知
公开(公告)号：ZA201300374B
公开(公告)日：2014-05-28
申请号：ZA201300374
申请日：2013-01-15
申请人： RIGEL PHARMACEUTICALS INC
发明人： GOFF DANE , PAYAN DONALD , SINGH RAJINGER , SHAW SIMON , CARROLL DAVID , HITOSHI YASUMICHI
IPC分类号： C07D20060101 , A61K20060101 , A61P20060101
摘要： wherein E, J, T, the ring system denoted by “B”, T, R3, R4, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.

43. 发明专利

CA2806341A1 AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME 未知
公开(公告)号：CA2806341A1
公开(公告)日：2012-02-02
申请号：CA2806341
申请日：2011-07-29
申请人： RIGEL PHARMACEUTICALS INC
发明人： GOFF DANE , PAYAN DONALD , SINGH RAJINDER , SHAW SIMON , CARROLL DAVID , HITOSHI YASUMICHI
IPC分类号： C07D213/82 , A61K31/4427 , A61K31/501 , A61K31/5377 , A61P3/10 , A61P9/10 , C07D295/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D471/10
摘要： Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure wherein E, J, T, the ring system denoted by "B", T, R3, R4, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.

44. 发明专利

SG172997A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER 未知
公开(公告)号：SG172997A1
公开(公告)日：2011-08-29
申请号：SG2011051174
申请日：2010-01-15
申请人： RIGEL PHARMACEUTICALS INC
发明人： HITOSHI YASUMICHI , HOLLAND SACHA , PAYAN DONALD G
摘要： This invention is directed to methods of preventing, treating or managing cancer, preferably metastatic cancer, in a patient. The methods comprise administering an effective amount of an AxI inhibitor in combination with the administation of an effective amount of one or more chemotherapeutic agents.

45. 发明专利

ES2320328T3 SAK: MODULACION DE LA PROLIFERACION CELULAR PARA EL TRATAMIENTO DEL CANCER. 未知
公开(公告)号：ES2320328T3
公开(公告)日：2009-05-21
申请号：ES02750377
申请日：2002-07-31
申请人： RIGEL PHARMACEUTICALS INC
发明人： DEMO SUSAN , HITOSHI YASUMICHI , JENKINS YONCHU
IPC分类号： C12Q1/68 , A61K38/00 , A61K39/395 , A61K48/00 , C12Q1/48 , G01N33/53 , G01N33/574
摘要： Un procedimiento para identificar un compuesto capaz de interferir con la unión de un polipéptido de SAK o un fragmento del mismo, comprendiendo el procedimiento las etapas de: (i) combinar un polipéptido de SAK o un fragmento del mismo con un polipéptido de Chk2 y el compuesto, en el que el polipéptido de SAK o el fragmento del mismo tiene actividad cinasa y está codificado por un ácido nucleico que hibrida bajo condiciones rigurosas a un ácido nucleico que codifica un polipéptido que tiene una secuencia de aminoácidos de SEC. ID Nº: 2; y (ii) determinar la unión del polipéptido de SAK o fragmento del mismo a Chk

46. 发明专利

AU2003223661A1 METHODS OF ASSAYING FOR CELL CYCLE MODULATORS 未知
公开(公告)号：AU2003223661A1
公开(公告)日：2003-11-03
申请号：AU2003223661
申请日：2003-04-15
申请人： RIGEL PHARMACEUTICALS INC
发明人： HITOSHI YASUMICHI , JENKINS YONCHU
IPC分类号： C12Q1/68 , G01N33/50 , G01N33/574 , G01N33/68
摘要： The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding BRCA-1-Associated Protein-1 (BAP-1), Nuclear Protein 95 (NP95), Fanconi anemia group A protein (FANCA), DEAD/H box polypeptide 9 (DDX9), insulin-like growth factor 1 receptor (IGF1R), ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1), aldehyde dehydrogenase, pyruvate kinase, glucose-6-phosphate dehydrogenase, HCDR-3, DEAD/H box polypeptide 21 (DDX21), serine threonine kinase 15 (ARK2), transmembrane 4 superfamily member 1, or ERCC1, which are involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of BRCA-1-Associated Protein-1 (BAP-1), Nuclear Protein 95 (NP95), Fanconi anemia group A protein (FANCA), DEAD/H box polypeptide 9 (DDX9), insulin-like growth factor 1 receptor (IGF1R), ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1), aldehyde dehydrogenase, pyruvate kinase, glucose-6-phosphate dehydrogenase, HCDR-3, DEAD/H box polypeptide 21 (DDX21), serine threonine kinase 15 (ARK2), transmembrane 4 superfamily member 1, or ERCC1, as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式